Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a substance called sulforaphane, which comes from broccoli, on children aged 6 to 12 who have Attention Deficit Disorder (ADD) with or without hyperactivity, often known as ADHD. ADHD is a common condition that affects a child's ability to pay attention and control their behavior. The research aims to see if sulforaphane can help improve the symptoms of ADHD in children who are diagnosed according to specific guidelines.

To participate in this study, children must be between 6 and 12 years old and have a diagnosis of ADHD. They need to be able to swallow capsules and have the support of a parent or guardian. However, children with certain conditions, such as allergies to broccoli or those who have received specific ADHD treatments recently, will not be eligible. The trial is not yet recruiting participants, but once it starts, families can expect to learn more about how sulforaphane may help children manage their ADHD symptoms. This could offer a new option for treatment alongside existing therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children aged 6 to 12
• • Diagnosis of ADHD according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders)
• • Followed or hospitalised in an investigating centre
• • Consent of holders of parental authority
• • Patient covered by health insurance (social security or CMU)
• • Patients able to swallow capsules
• Exclusion Criteria:
• • Allergy to broccoli
• • Psychotropic treatment including methylphenidate in the month prior to inclusion
• • Ongoing psychotherapeutic and/or psycho-educational treatment specific to ADHD
• • ASD (Autism Spectrum Disorder) according to DSM-5 criteria, intellectual disability (IQ\< 80)
• • Chronic neurological disease, epilepsy
• • Holders of parental authority under guardianship or curatorship
• • Previous intake of sulforaphane
• • Known hypothyroidism or current thyroid treatment
• • Participation in other interventional research involving the human person or being within the exclusion period following previous research involving the human person, where applicable
• • Patient under AME (state medical aid)